KRAS and non-small cell lung carcinoma: Johnson et al. (2013) [30] has suggested the KRAS mutation predicts a shorter survival for patients with advanced lung adenocarcinoma, however Bauml et al. (2013) [31] did not determine that EGFR and KRAS had prognostic abilities for advanced NSCLC.